Studies on chronic antibiotic refractory pouchitis highlight limited evidence for non-pharmacologic therapies while demonstrating efficacy of biologic therapies such as mesalamine, budesonide, anti-tumor necrosis factor alpha therapies, ustekinumab, and vedolizumab in managing the condition. Biologic therapies offer a steroid-sparing option, with vedolizumab showing favorable results in randomized controlled trials. Non-medication therapies like hyperbaric oxygen and fecal microbiota transplant require further research for accessibility.
Journal Article by Weber AT and Lichtenstein GR in Dis Colon Rectum
Copyright © The ASCRS 2024.